KAHR Medical focuses on advancing cancer therapy through innovative approaches that target immune checkpoints, which are molecules that regulate the immune system's ability to distinguish between healthy cells and cancer cells. The company has developed a versatile immuno-therapeutic platform known as Multifunctional Immuno-Recruitment Proteins (MIRPs). These proteins are designed to trigger a multilayered immune response by inhibiting key evasion markers on cancer cells, thereby exposing them for recognition and attack by the innate immune system. MIRPs can activate both innate and adaptive immunity, leading to the selective elimination of cancer cells. They are built in two configurations: Dual Signaling Proteins (DSPs) and DSPs with an Fc domain (DSP-Fc), each utilizing different strategies to enhance the immune response while minimizing potential cytotoxicity to healthy tissues.

KAHR Medical's pipeline includes a range of drug candidates that target multiple immune checkpoints and various cancer types, with the potential to treat both solid and hematological malignancies. The DSPs are designed to selectively bind to overexpressed checkpoints on cancer cells, activating T-cells and enhancing anti-tumor sensitivity. The DSP-Fc configuration further improves tumor targeting by binding to multiple checkpoint ligands, facilitating a synergistic immune response. KAHR is actively exploring the effects of these candidates both as standalone therapies and in combination with existing immunotherapies, collaborating with leading pharmaceutical companies and medical centers to advance their clinical applications.

Israel

KAHR Medical is developing an innovative and novel drug platform of immunotherapeutic bi-functional fusion proteins that harness the human immune system to target multiple cancer indications

KAHR Medical

Company Details